Description
MAPT Antibody | 30-353 | Gentaur UK, US & Europe Distribution
Host: Rabbit
Reactivity: Human
Homology: N/A
Immunogen: Antibody produced in rabbits immunized with a synthetic peptide corresponding a region of human MAPT.
Research Area: Cancer
Tested Application: E, WB
Application: MAPT antibody can be used for detection of MAPT by ELISA at 1:312500. MAPT antibody can be used for detection of MAPT by western blot at 0.5 μg/mL, and HRP conjugated secondary antibody should be diluted 1:50, 000 - 100, 000.
Specificiy: N/A
Positive Control 1: Cat. No. 1211 - HepG2 Cell Lysate
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: 46 kDa, 40 kDa, 79 kDa, 37 kDa
Validation: N/A
Isoform: N/A
Purification: Antibody is purified by peptide affinity chromatography method.
Clonality: Polyclonal
Clone: N/A
Isotype: N/A
Conjugate: Unconjugated
Physical State: Liquid
Buffer: Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Concentration: batch dependent
Storage Condition: For short periods of storage (days) store at 4˚C. For longer periods of storage, store MAPT antibody at -20˚C. As with any antibody avoid repeat freeze-thaw cycles.
Alternate Name: MAPT, DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, TAU
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: MAPT is differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. The mutations in the gene have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.